Optimal approach to prevent veno-occlusive disease following hematopoietic stem cell transplantation in children.
Hassan
Zuzana
Z
D002756:Cholagogues and Choleretics / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006504:Hepatic Veno-Occlusive Disease / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D006801:Humans; D011089:Polydeoxyribonucleotides / Q000627:therapeutic use; D012307:Risk Factors; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use
D002756:Cholagogues and Choleretics; D005343:Fibrinolytic Agents; D011089:Polydeoxyribonucleotides; C036901:defibrotide; D014580:Ursodeoxycholic Acid